Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone - Seite 2

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca.

References

1. Market Scope - 2023 Premium Cataract Surgery Market Report; 2023 IOL Market Report.
2. Alcon Data on File, US Patent 9968440 B2, May 15, 2018.
3. AcrySof IQ Vivity or Clareon IQ Vivity IOL Directions for Use.
4. Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes from a Real-world Study of Presbyopia-correcting IOLs in a Large Population. Presented at the European Society of Cataract and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept, 2023; Vienna, Austria.
5. Promotional Claim Supporting information PanOptix PC-IOL Family Product Code TFNT00.
6. Alcon IOL Global Sales; Jan 2021- Nov 2022.

* Based on worldwide sales of AcrySof IQ Vivity and Clareon Vivity IOLs
•Presbyopia Correcting Intraocular Lens
+The Vivity Registry Study was a multicentre, ambispective, non-comparative, open-label, non-interventional registry study conducted across 41 sites from eight (8) countries: Australia, Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain and the United Kingdom.
^‡CATQUEST 9SF, patients were asked: Do you have difficulty with the activities because of your sight? If so, to what extent?
^∞Subject satisfaction was evaluated with the Catquest 9SF Questionnaire. Statistic refers to ‘very’ or ‘fairly’ satisfied.
^†Visual disturbances were evaluated by asking open, non-prompted questions about visual experience.
^§IOLSAT: In the past 7 days, how often did you need to wear eyeglasses to see?
¤ Based on Alcon IOLs worldwide unit Sales, 2022

Connect with us on
Facebook
LinkedIn

Please refer to the product direction for use for a complete list of indications, contraindications and warnings.

2024 Alcon Inc. CA-VIV-2400002

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306570437/en/

The Alcon Stock at the time of publication of the news with a raise of +0,60 % to 78,82EUR on Lang & Schwarz stock exchange (06. März 2024, 15:55 Uhr).